eceptor so that the drug does not bind permanently to the receptor, and the receptor and the platelet can regain function, with normal platelet clotting ability returning in about four days, which may explain the absence of increased bleeding with ticagrelor," Steg said. "However, ticagrelor does have off-target effects, which probably explain a side effect more commonly seen with ticagrelor than clopidogrel: dyspnea, or breathlessness, which affected 12.9 percent of ticagrelor patients and 8.3 percent of the clopidogrel group."
Overall mortality was reduced with ticagrelor -- from 6.0 percent to 4.9 percent, a relative reduction of risk of 18 percent. Likewise, the risk of new myocardial infarction and the risk of stent thrombosis were also reduced. "Furthermore, the benefit is not solely achieved during the acute phase, the first 30 days after angioplasty, but the benefit accrues over time so that the longer you treat, the greater the difference in event rates," Steg said. "There is a strong rationale to prefer this new agent both in the acute (first 30 days) and in the late phase after a heart attack."
Study funded by: AstraZeneca (manufacturer of the investigational drug).
Co-authors are: Richard C. Becker, M.D.; Christopher P. Cannon, M.D.; Hakan Emanuelsson, M.D., Ph.D.; Robert A. Harrington, M.D.; Jay Horrow, M.D.; Steen Husted, M.D., D.Sc.; Hugo Katus, M.D.; Robert F. Storey, M.D., D.M.; Lars C. Wallentin, M.D., Ph.D.
Disclosures: Research grant: Sanofi-Aventis, Servier Speakers bureau: Boehringer-Ingelheim, BMS, GSK, Medtronic, Sanofi-Aventis, Servier, The Medicines Company. Consulting/advisory board: Astellas, AstraZeneca, Bayer, Boehringer-Ingelheim, BMS, Endotis, GSK, Medtronic, MSD, Nycomed, Sanofi-Aventis, Servier, and The Medicines Company.
Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and
Page: 1 2 3 4 Related medicine technology :1
|SOURCE American Heart Association|
Copyright©2009 PR Newswire.
All rights reserved
. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA2
. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate3
. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.4
. Aspirin Named 8th World Wonder by Majority of Americans5
. MedImmunes Motavizumab Reduced RSV Hospitalizations by 83 Percent Among High-Risk Native American, Full-Term Infants in Placebo-Controlled Phase 3 study6
. American Heart Association Comment Saving Lives in Type 2 Diabetics: Could It Be as Easy as Lowering Blood Pressure?7
. TrialCheck(R) Cancer Clinical Trial Matching Interface to Debut on American Cancer Society Web Site8
. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care9
. Positive Results for NKTR-118 (oral PEG-naloxol) Presented at American Academy of Pain Management Meeting10
. Preimplantation Genetic Diagnosis International Society Refutes American Society of Reproductive Medicine Opinion - States Preimplantation Genetic Screening is Beneficial When Performed in Experienced Centers11
. New MIRCERA(R) Data Analyses to be Featured at the American Society of Nephrology Annual Meeting